---
layout: default
title: Milrinone
parent: 僅模型預測 (L5)
nav_order: 422
evidence_level: L5
indication_count: 10
---

# Milrinone
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Milrinone: From Acute Decompensated Heart Failure to Alopecia

## One-Sentence Summary

> Milrinone's original indication data is missing from this registry pack, but based on established pharmacology it is a PDE3 inhibitor used as a short-term IV inotrope/vasodilator for acute decompensated heart failure and cardiogenic shock.
> The TxGNN model predicts it may be effective for **Alopecia**, the single highest-scoring prediction in this evidence pack (score ≈99.91%),
> but currently **0 clinical trials** and **0 publications** support this specific drug–indication pairing — the prediction is model-only.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not present in this pack (`original_indications` empty). Based on known pharmacology: short-term IV management of acute decompensated heart failure / cardiogenic shock |
| Predicted New Indication | Alopecia |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | 未上市 (Not Marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap, DG002). Based on known information, milrinone is a selective phosphodiesterase-3 (PDE3) inhibitor that raises intracellular cAMP in cardiac and vascular smooth muscle, producing a combined positive-inotropic and vasodilating ("inodilator") effect. Its efficacy in acute decompensated heart failure/cardiogenic shock is well documented in the literature captured elsewhere in this pack (see the congestive heart failure and acute pulmonary heart disease predictions), even though this drug is not currently registered or marketed in this market.

The rationale for alopecia is purely mechanistic and speculative: PDE3 inhibition → increased cAMP → localized vasodilation is theorized to run parallel to minoxidil's mechanism (a K⁺-channel opener that promotes follicular blood flow and is an established alopecia treatment). However, there is no direct evidence that PDE3 inhibition specifically affects the hair follicle growth cycle — the analogy is structural (both are vasodilators) rather than mechanistically validated.

The TxGNN score for this pairing is extremely high (rank 2154 among all predictions), but the evidence pack explicitly classifies it as **L5 (model prediction only, no actual studies)** with a **Hold** recommendation. No clinical trials, ICTRP records, or PubMed literature were returned for the milrinone–alopecia pairing in any query.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Saudi Arabia Market Information

Milrinone is not currently registered or marketed in this jurisdiction (`market_status`: 未上市, 0 total authorizations, no license records available).

---

## Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are all flagged as data gaps in this pack; TFDA package-insert warnings/contraindications are listed as Blocking data gap DG001, which prevents entry into the S1 safety pre-assessment stage.)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Despite the very high TxGNN score, this is a purely computational prediction (L5) with zero supporting clinical trials or literature, and the proposed PDE3-to-hair-follicle mechanism is unvalidated speculation rather than an established pharmacological link.

**To proceed, the following is needed:**
- Preclinical or mechanistic data establishing whether PDE3 inhibition/vasodilation affects the hair follicle growth cycle
- Any exploratory clinical data (case reports, pilot studies) testing milrinone (topical or systemic) specifically for alopecia
- Resolution of DG001 (TFDA/SFDA package insert warnings and contraindications) and DG002 (MOA) before this candidate can even enter safety pre-assessment
- Confirmation of milrinone's actual original indication and regulatory status, since `original_indications` is empty despite the drug's well-established clinical use in heart failure
- Note: within this same evidence pack, **congestive heart failure** (rank 6, L1, Proceed with Guardrails) and **acute pulmonary heart disease** (rank 10, L2, Proceed with Guardrails) have substantially stronger evidence bases and may be higher-priority repurposing candidates for this drug than alopecia
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

